HORSHAM, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (“STRATA”) a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of dermatological disorders, announced today that it will host a Key Opinion Leader meeting on Thursday, June 16th at 12pm ET in New York City.
The meeting will feature keynote presentations by renowned dermatological experts R. Rox Anderson, MD and Noah S. Scheinfeld, JD, MD, who will discuss new approaches to treating serious dermatological disorders, including psoriasis and vitiligo. Members of the STRATA Skin Sciences executive management team will provide an overview of the Company’s XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
Dr. Rox Anderson serves as Director of Massachusetts General Hospital’s Wellman Center for Photomedicine, the world’s largest academic facility dedicated to photomedicine. He is also a professor at Harvard Medical School and an adjunct professor at MIT. Dr. Anderson was previously President of the American Society for Laser Medicine & Surgery, where he now serves as Director of Government Communications and Education. He currently serves on STRATA Skin Sciences’ Board of Directors.
Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in dermatology, such as selective photothermolysis for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. His research has significantly advanced the knowledge of human skin photobiology, drug photosensitization mechanisms, and laser-tissue interactions, and has contributed to the development of tissue optics, photodynamic therapy, and optical diagnostics.
Dr. Anderson graduated from MIT, received his MD degree magna cum laude from the joint MIT-Harvard Medical Program, Health Sciences and Technology, and completed his residency in dermatology and research fellowships at Harvard.
Dr. Noah Scheinfeld maintains a private dermatology practice in New York City. He is also an Assistant Clinical Professor of Dermatology at Columbia University Medical Center and serves as an Assistant Attending Physician at Beth Israel Medical Center and St. Luke's Roosevelt Hospital Center.
Dr. Scheinfeld is a nationally recognized expert on psoriasis, hidradenitis suppurativa & Degos disease. As of 2010, he has authored or coauthored more than 175 peer-reviewed articles and has given more than 60 national dermatology presentations. He is an editor for Journal Drugs & Dermatology, SKINmed, Cutis, Skin & Aging, Dermatology Online Journal & American Journal of Clinical Dermatology.
Dr. Scheinfeld graduated magna cum laude from Columbia University. He received his JD from Harvard Law School and his MD from Yale University School of Medicine. He completed his residency in dermatology at Albert Einstein College of Medicine and has been certified by the American Board of Dermatology in Dermatology and Pediatric Dermatology.
The event is intended for institutional investors and sell-side analysts only. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at mac@lifesciadvisors.com to reserve a place.
A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20160616/reg.jsp and in the Investors section of the Company’s website at http://strataskinsciences.com.
About STRATA Skin Sciences, Inc. (www.strataskinsciences.com)
STRATA Skin Sciences is a medical technology company focused on the therapeutic and diagnostic dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions, and the MelaFind® system used to assist in the identification and management of melanoma skin cancer.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, including the Company’s ability to generate the anticipated revenue stream, the Company’s ability to generate sufficient cash flow to fund the Company’s ongoing operations beginning at any time in the future, the public’s reaction to the Company’s new advertisements and marketing campaign, and the Company’s ability to build a leading franchise in medical dermatology, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.